Merck have announced a partnership with Oxford University’s Jenner Institute to develop more robust and scalable vaccine manufacturing processes. The aim of the partnership is to make vaccines more affordable and available globally.
Through the collaboration with the Jenner Institute, the partners will improve the manufacturing process for adenovirus vaccines (vaccines based on adenovirus, a type of DNA virus, as a carrier) on a real-world feed stream. The collaborators aim to develop a cost-effective and transferable manufacturing process that can be used to accelerate vaccine development and manufacturing worldwide.
Adrian Hill, Director of the Jenner Institute at Oxford University said, “The newly developed process should match or exceed our existing process in terms of productivity and purity. Such improvements should help advance the development of clinical-grade, injectable drug product for use in clinical trials and other research applications,” Hill added.